Literature DB >> 9313632

A review of erythromycin-induced malignant tachyarrhythmia--torsade de pointes. A case report.

K Katapadi1, G Kostandy, M Katapadi, K M Hussain, D Schifter.   

Abstract

The term torsade de pointes refers to a ventricular tachycardia characterized by QRS complexes of changing amplitude that appears to twist around the isoelectric line and occurs at rates of 200-250/minute. Most cases of torsade de pointes are iatrogenically induced by drugs or electrolyte abnormalities. The most important feature is QT interval prolongation. Torsade de pointes was first described in 1966 in France by Dessertenne. The authors report a case of a fifty-year-old woman with medical history of corrective surgery for tetralogy of Fallot who was admitted to the hospital with pneumonia and atrial fibrillation and later developed recurrent episodes of polymorphic ventricular tachycardia with QT interval prolongation after i.v. administration of erythromycin. The episodes did not recur after discontinuation of erythromycin, and the QT interval returned to normal. The association of erythromycin with torsade de pointes has been reported in 18 cases to date. Erythromycin has been shown to produce electrophysiologic effects similar to those of class Ia and class III antiarrhythmic drugs on the cardiac muscle. This potentially fatal complication of a commonly used antibiotic is rare, but increased physician awareness is important, especially in patients with predisposing factors like electrolytes abnormalities, use of class Ia and Class III antiarrhythmic drugs, and presence of prolonged QT interval (congenital prolonged QT syndromes). This is the second case reported in a patient with previous cardiac surgery and erythromycin administration.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9313632     DOI: 10.1177/000331979704800909

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  10 in total

1.  Comparative pharmacodynamic analysis of Q-T interval prolongation induced by the macrolides clarithromycin, roxithromycin, and azithromycin in rats.

Authors:  H Ohtani; C Taninaka; E Hanada; H Kotaki; H Sato; Y Sawada; T Iga
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

Review 2.  Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling.

Authors:  M Malik; A J Camm
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 3.  Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.

Authors:  G K Dresser; J D Spence; D G Bailey
Journal:  Clin Pharmacokinet       Date:  2000-01       Impact factor: 6.447

Review 4.  Macrolides for the prevention and treatment of feeding intolerance in preterm low birth weight infants: a systematic review and meta-analysis.

Authors:  Sriparna Basu; Susan Smith
Journal:  Eur J Pediatr       Date:  2020-10-12       Impact factor: 3.183

Review 5.  Drug-induced proarrhythmia: risk factors and electrophysiological mechanisms.

Authors:  Gerrit Frommeyer; Lars Eckardt
Journal:  Nat Rev Cardiol       Date:  2015-07-21       Impact factor: 32.419

6.  Characterization of the inhibitory effects of erythromycin and clarithromycin on the HERG potassium channel.

Authors:  Scott J C Stanat; Carol G Carlton; William J Crumb; Krishna C Agrawal; Craig W Clarkson
Journal:  Mol Cell Biochem       Date:  2003-12       Impact factor: 3.396

Review 7.  QT prolongation with antimicrobial agents: understanding the significance.

Authors:  Robert C Owens
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Use and Safety of Erythromycin and Metoclopramide in Hospitalized Infants.

Authors:  Jessica E Ericson; Christopher Arnold; Jomani Cheeseman; Jordan Cho; Sarah Kaneko; Ele'na Wilson; Reese H Clark; Daniel K Benjamin; Vivian Chu; P Brian Smith; Christoph P Hornik
Journal:  J Pediatr Gastroenterol Nutr       Date:  2015-09       Impact factor: 3.288

9.  Use of clarithromycin and roxithromycin and risk of cardiac death: cohort study.

Authors:  Henrik Svanström; Björn Pasternak; Anders Hviid
Journal:  BMJ       Date:  2014-08-19

10.  Erythromycin, QTc interval prolongation, and torsade de pointes: Case reports, major risk factors and illness severity.

Authors:  Jules C Hancox; Mehrul Hasnain; W Victor R Vieweg; Michael Gysel; Michelle Methot; Adrian Baranchuk
Journal:  Ther Adv Infect Dis       Date:  2014-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.